DAX22.065 +0,5%ESt505.115 +0,3%Top 10 Crypto12,43 -0,3%Dow40.057 +1,1%Nas17.099 +2,3%Bitcoin82.171 -0,5%Euro1,1373 +0,4%Öl66,56 +0,6%Gold3.331 +1,3%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 NVIDIA 918422 Tesla A1CX3T RENK RENK73 BYD A0M4W9 SAP 716460 Infineon 623100 Mercedes-Benz Group (ex Daimler) 710000 Lufthansa 823212 Amazon 906866 Siemens Energy ENER6Y Volkswagen (VW) vz. 766403 BASF BASF11 Allianz 840400 Apple 865985
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Berichtssaison im Blick: DAX höher -- adidas steigert Umsatz und Gewinn -- SAP beginnt 4. Aktienrückkaufrunde -- Newmont, IBM, Siemens Energy, Luxuswerte & Tesla im Fokus
Top News
Uniper-Aktie gibt nach: Verlust zum Jahresstart - Ergebnisausblick bestätigt Uniper-Aktie gibt nach: Verlust zum Jahresstart - Ergebnisausblick bestätigt
EVOTEC-Aktie höher: Erfolgszahlungen von Bristol Myers Squibb EVOTEC-Aktie höher: Erfolgszahlungen von Bristol Myers Squibb
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Die Top 10 Coins im Depot - mit dem finanzen.net Top 10 Crypto ETP. Jetzt informieren!

Spyre Therapeutics Aktie

NeuKaufenVerkaufen
12,50 EUR -0,10 EUR -0,79 %
STU
14,75 USD +0,51 USD +3,58 %
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Bei einem anderen Broker handelnSmartphone

Marktkap.753,34 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA3D4LY

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS00773J2024

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolSYRE

Spyre Therapeutics Aktien News

DatumMeistgelesen
PR NewswireSpyre Therapeutics Announces Grants of Inducement Awards
PR NewswireSpyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody
PR NewswireSpyre Therapeutics Announces Grants of Inducement Awards
PR NewswireSpyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
PR NewswireSpyre Therapeutics to Participate in Upcoming March Investor Conferences
PR NewswireSpyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation
PR NewswireSpyre Therapeutics Announces Grants of Inducement Awards
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
PR NewswireSpyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
PR NewswireSpyre Therapeutics Announces Grants of Inducement Awards
PR NewswireSpyre Therapeutics Added to the Nasdaq Biotechnology Index
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
PR NewswireSpyre Therapeutics Announces Grants of Inducement Awards
PR NewswireSpyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
PR NewswireSpyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
PR NewswireSpyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-α4β7 Antibody for the Treatment of Inflammatory Bowel Disea...
PR NewswireSpyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-α4β7 Antibody for the Treatment ...
PR NewswireSpyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
PR NewswireSpyre Therapeutics Announces Grants of Inducement Awards
PR NewswireSpyre Therapeutics to Participate in Upcoming November Investor Conferences
PR NewswireSpyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and Combin...
PR NewswireSpyre Therapeutics Announces Grants of Inducement Awards
PR NewswireSpyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer
PR NewswireSpyre Therapeutics to Participate in Upcoming Investor Conference
PR NewswireSpyre Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
PR NewswireSpyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-α4β7 Antibody, for the Treatment of Inflammatory Bowel Disease
PR NewswireSpyre Therapeutics Announces Grants of Inducement Awards
PR NewswireSpyre Therapeutics to Participate in the Jefferies Global Healthcare Conference
PR NewswireSpyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors
PR NewswireSpyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
PR NewswireSpyre Therapeutics Announces Grants of Inducement Awards
PR NewswireSpyre Therapeutics Announces Grants of Inducement Awards
PR NewswireSpyre Therapeutics Announces Grants of Inducement Awards
PR NewswireSpyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
PR NewswireSpyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference
PR NewswireSpyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn's and Colitis Organisation
PR NewswireSpyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors
Wer­bung

Spyre Therapeutics News

Spyre Therapeutics News: auf dieser Seite finden Sie alle Spyre Therapeutics News und Nachrichten zur Spyre Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Spyre Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Spyre Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.